Run multiple projects per plate, each processed against matrix-specific libraries built on historical knowledge, maximizing instrument utilization and scientific rigor in a single workflow. Every user, regardless of study size, has direct access to the Integrated Bioinformatics Platform, a comprehensive analytical environment for statistical modeling, pathway analysis, and multi-omics integration.
Offer a metabolomics capability that is standardized, reproducible, and globally comparable, positioning the CRO as a premium partner for preclinical, late-stage studies, and sponsor-critical programs where reproducible data quality is non-negotiable. Detect pathway-level metabolic shifts linked to efficacy, safety, and patient response across in vitro, in vivo, and ex vivo models, providing clients with the biomarker and mechanistic evidence needed to make faster, better-informed go/no-go decisions.
Deploy validated, standardized LC-MS workflows immediately, eliminating the typical 6–12 months of method optimization required to establish reliable metabolomics workflows in a new laboratory and dramatically reducing the total cost and time required to launch metabolomics capabilities.
Interrogate the exposome, microbiome, and host metabolic pathways within a single experiment, generating the biological breadth needed to understand how diet, environment, and metabolism converge on disease mechanisms.
Integrate metabolomics with other data modalities to build a more complete biological picture, strengthening the evidence base for clinical success, label expansion, and patent protection.
Incorporate metabolomics across clinical programs at any scale, from early translational studies through to multi-site Phase III trials, with data quality and reproducibility that meets the demands of each stage.